Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance

We read with much pleasure the article by Di Maio et al. A major strength of this article is the authors' ability to share data with three sponsors. Promoters of clinical trials usually tend to emphasize, for obvious commercial reasons, their effectiveness rather than their negative implications, like adverse effects. The authors consistently discussed important issues; however, we would like to add the following considerations that may reinforce their results.